TLDR Specific mutations in a receptor cause facial abnormalities and hair loss.
The study identifies gain-of-function mutations in the endothelin receptor type A (ETAR), specifically p.E303K and p.Y129F, as causes of mandibulofacial dysostosis with alopecia (MFDA). These mutations enhance the receptor's affinity for endothelin 3 (ET3), leading to craniofacial abnormalities and alopecia. Mouse models with these mutations showed similar changes, which were partially reversed by deleting ET3, indicating the mutations' effects are largely ET3-dependent. The research highlights the role of allosteric effects in GPCR function and suggests potential drug targets for treating MFDA.
11 citations
,
March 2020 in “American Journal of Medical Genetics Part A” A mutation in the EDNRA gene causes Oro-Oto-Cardiac syndrome, affecting face and heart development.
59 citations
,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
12 citations
,
December 2010 in “Journal of thoracic oncology” New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
11 citations
,
March 2020 in “American Journal of Medical Genetics Part A” A mutation in the EDNRA gene causes Oro-Oto-Cardiac syndrome, affecting face and heart development.
5 citations
,
November 1999 in “Medical Hypotheses” Minoxidil, a common hair loss treatment, might work by counteracting a hormone that reduces hair growth and promotes hair loss.
25 citations
,
June 2018 in “Journal of The American Academy of Dermatology” Genes linked to fibrosis are more active in people with central centrifugal cicatricial alopecia.